To confirm the effect of Susu Xiaoer Zhike granules in treating cough caused by common cold (wind-cold cough Syndromes) in children aged 6\~13 years, shortening the course of disease and improving symptoms.
It met the diagnostic criteria for common cold, and the severity VAS score of day or night cough was ≥40 mm ，the cough symptom score was ≥2 points;
Conforming to the standard of wind-cold cough differentiation;
Age 6-13 years old (6 years old ≤ age < 14 years old);
Duration of cough ≤48 hours;
accompanied by pharyngeal swelling pain, heat image is obvious;
White blood cell count, neutrophils absolute value, C-reactive protein, all exceeded the upper limit of 1.2 times the reference value, and the researchers considered the bacterial infection;
there have been complications (bacterial otitis media, sinusitis, suppurative tonsillitis, bronchitis, bronchopneumonia);
Patients with acute bronchitis and pneumonia cured less than 8 weeks;
Parallel
Susu Xiao'er Zhike Granules
DrugSusu Xiao'er Zhike Granules 1 bag(7g granule per bag,contains 20.25 g crude herbs), twice a day for five days
Extremely-low dose Susu Xiao'er Zhike Granules
DrugExtremely-low dose Susu Xiao'er Zhike Granules 1 bag (7g granule per bag,contains 1.01 g crude herbs), twice a day for five days
Cough disappearance rate
Cough symptom scores were recorded at baseline and daily after treatment and evaluated at the end of treatment (Patients whose cough did not disappear were followed up for 24 hours).
Cough symptom score
Baseline and post-treatment were recorded daily, and diachronic changes were evaluated at the end of treatment.
VAS score of cough symptoms
Baseline and post-treatment were recorded daily, and diachronic changes were evaluated at the end of treatment.
Time to disappearance of cough
Cough symptom scores were recorded at baseline and daily after treatment and evaluated at the end of treatment (Patients whose cough did not disappear were followed up for 24 hours).
Onset time of cough
Cough VAS score were recorded at baseline and daily after treatment and evaluated at the end of treatment
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
